chief operating officer, Edward Jacobs, will leave the company at year-end and the company will eliminate the COO position after he's gone.
Jacobs will leave after the expected completion of the sale of Nipent (pentostatin for injection) and SurfaceSafe to
. Jacob's "departure reflects the shift in SuperGen's focus to the development of a pipeline of next-generation anticancer therapies," the company said.
"During (Jacob's) tenure, SuperGen was able to develop and grow the Nipent franchise, launch operations in Europe, license Dacogen and secure several significant commercial partnerships, " CEO James Manuso said. "With our financial engine in place and growing, we are turning our attention to the discovery, development, partnering and ultimate commercialization of proprietary anticancer drugs."
Shares of Supergen were higher in after-market trading Wednesday, up 17 cents, or 3.5%, at $4.97 recently.